Whether it is possible to spend on drink eskuzan at a puffiness of a breast

In this article, you can read the instructions for using the drug Nimesil. Presented reviews of visitors to the site -consumers of this medicine, as well as the opinions of doctors of specialists on the use of Nimesil in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Nimesil with available structural analogues. Use to treat and stop pain in various diseases in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Nimesil - Non-steroidal anti-inflammatory drug fromclass sulfonamides. Has anti-inflammatory, analgesic and antipyretic effect. Nimesulide acts as an inhibitor of the cyclooxygenase enzyme responsible for the synthesis of prostaglandins and inhibits mainly cyclooxygenase-2.

Nimesulide + excipients.

After ingestion, the drug is well absorbedfrom the digestive tract. Easily penetrates through the histohematological barriers. Nimesulide (the active substance of the drug Nimesil) is excreted from the body, mainly by the kidneys (about 50% of the dose taken). When you re-take the drug cumulation is not observed.

  • treatment of acute pain (back pain, lower back pain, pain syndrome in the musculoskeletal system, including injuries, sprains and joints dislocation, tendenitis, bursitis, toothache);
  • symptomatic treatment of osteoarthritis with pain syndrome;
  • algodismenorea.

The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use.

Powder or granules for the preparation of a suspension for ingestion 100 mg.

Forms in the form of tablets at the time of the description of the drug in the directory did not exist.

Instructions for use and reception scheme

Nimesil is taken orally, 1 packet (100 mgnimesulide) 2 times a day. The drug is recommended after eating. The contents of the sachet are poured into a beaker and dissolved in about 100 ml of water. The prepared solution is not subject to storage.

Nimesil is used only for the treatment of patients older than 12 years.

Adolescents (aged 12 to 18 years): based on the pharmacokinetic profile and pharmacodynamic characteristics of nimesulide, there is no need to adjust the dose in adolescents.

Elderly patients: in the treatment of elderly patients, the need to adjust the daily dose is determined by the physician based on the possibility of interaction with other medicines.

The maximum duration of treatment with nimesulide is 15 days.

To reduce the risk of undesirable side effects, use the lowest effective dose with a minimally short course.

  • anemia;
  • eosinophilia;
  • hemorrhagic syndrome;
  • thrombocytopenia;
  • pancytopenia;
  • thrombocytopenic purpura;
  • itching;
  • rash;
  • increased sweating;
  • dermatitis;
  • anaphylactoid reactions;
  • hives;
  • angioedema;
  • dizziness;
  • nervousness;
  • headache;
  • drowsiness;
  • blurred vision;
  • arterial hypertension;
  • tachycardia;
  • dyspnea;
  • exacerbation of bronchial asthma;
  • bronchospasm;
  • diarrhea, constipation;
  • nausea, vomiting;
  • stomach ache;
  • dyspepsia;
  • stomatitis;
  • tarry stools;
  • gastrointestinal bleeding;
  • ulcer and / or perforation of the stomach or duodenum;
  • jaundice;
  • hematuria (blood in the urine);
  • retention of urination;
  • hyperkalemia.
  • hyperergic reactions in the anamnesis, for example,bronchospasm, rhinitis, urticaria, associated with the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs), incl. nimesulide;
  • hepatotoxic reactions to nimesulide in the anamnesis;
  • concomitant (simultaneous) administration of drugs with potential hepatotoxicity, for example, paracetamol or other analgesic or non-steroidal anti-inflammatory drugs;
  • inflammatory bowel disease (Crohn's disease, ulcerative colitis) in the phase of exacerbation;
  • period after aortocoronary shunting;
  • fever in infectious and inflammatory diseases;
  • complete or partial combination of bronchial asthma, recurrent nasal polyposis or paranasal sinuses with intolerance to acetylsalicylic acid and other NSAIDs (including in the anamnesis);
  • peptic ulcer of the stomach and duodenum in the phase of exacerbation, the presence of an ulcer in an anamnesis, perforation or bleeding in the gastrointestinal tract;
  • the presence in the anamnesis of cerebrovascular vascular bleeding or other bleeding, as well as diseases accompanied by bleeding;
  • severe blood clotting disorders;
  • severe heart failure;
  • severe renal failure (QC <30 ml / min), confirmed hyperkalemia;
  • hepatic insufficiency or any active liver disease;
  • children's age till 12 years;
  • pregnancy and the period of breastfeeding;
  • alcoholism (simultaneous reception with alcohol is prohibited because of the risk of bleeding from the digestive tract), drug dependence;
  • hypersensitivity to the components of the drug.

Application in pregnancy and lactation

As with other NSAID-class products,inhibit the synthesis of prostaglandins, Nimesil can adversely affect the course of pregnancy and / or the development of the embryo and can lead to premature closure of the arterial duct, hypertension in the pulmonary artery system, renal dysfunction that can turn into kidney failure with oligodrainage, an increased risk of bleeding, decrease the contractility of the uterus, the occurrence of peripheral edema. In this regard, the drug is contraindicated in pregnancy and during breastfeeding.

Unwanted side effects can be minimized by using the lowest effective dose of the drug as little as possible a short course.

Nimesil should be used with caution in patients with gastrointestinal ailments in history (ulcerative colitis, Crohn's disease), as possible exacerbation of these diseases.

The risk of gastrointestinalbleeding, ulcers or perforations of the ulcer increases with an increase in the dose of NSAIDs in patients with a history of an ulcer, especially complicated by bleeding or perforation, as well as in elderly patients, so treatment should begin at the lowest possible dose. Patients receiving medications that reduce blood clotting or suppress platelet aggregation also increase the risk of gastrointestinal bleeding. In case of gastrointestinal bleeding or ulcers in patients taking Nimesil, treatment with the drug should be discarded.

Since Nimesil is partially excreted by the kidneys, its dosage for patients with impaired renal function should be reduced, depending on the level of urination.

There are data on the occurrence of rare casesreactions from the liver. If there are signs of liver damage (itchy skin, yellowing of the skin, nausea, vomiting, abdominal pain, darkening of the urine, increased activity of "liver" transaminases), stop taking the drug and consult your doctor.

Despite the rarity of violationsin patients taking nimesulide concomitantly with other NSAIDs, treatment should be discontinued immediately. If any visual impairment occurs, the patient should be examined by an oculist.

The drug can cause fluid retention in the tissues, so patients with high blood pressure and with cardiac abnormalities Nimesil should be used with extreme caution.

In patients with renal or cardiacThe use of Nimesil should be used with caution, since kidney function may worsen. In case of deterioration, treatment with Nimesil must be discontinued.

Clinical studies and epidemiologicalthe data allow to conclude that NSAIDs, especially in high doses and with long-term use, can lead to an insignificant risk of myocardial infarction or stroke. To exclude the risk of such events occurring when nimesulide is used, data is insufficient.

The composition of the drug includes sucrose, it followsConsider patients with diabetes mellitus (0.15-0.18 XE per 100 mg of the drug) and those who follow a low-calorie diet. Nimesil is not recommended for patients with rare hereditary diseases of intolerance to fructose, malabsorption of glucose-galactose or insufficiency of sucrose-isomaltose.

If there are signs of "cold" or acute respiratory viral infection in the process of treatment with Nimesil, the drug should be stopped.

Do not use Nimesil concomitantly with other NSAIDs.

Nimesulide can alter the properties of platelets,therefore it is necessary to be careful when using the drug in people with hemorrhagic diathesis, but the drug does not replace the preventive effect of acetylsalicylic acid in cardiovascular diseases.

Elderly patients are particularlyadverse reactions to NSAIDs, including the occurrence of gastrointestinal bleeding and perforations that threaten the patient's life, worsening kidney, liver and heart function. When Nimesil is taken for this category of patients, proper clinical control is necessary.

As with other NSAID-class products,inhibit the synthesis of prostaglandins, nimesulide can adversely affect the course of pregnancy and / or the development of the embryo and can lead to premature closure of the arterial duct, hypertension in the pulmonary artery system, renal dysfunction, which can translate into kidney failure with oligodrainage, an increased risk of bleeding, decrease the contractility of the uterus, the occurrence of peripheral edema. In this regard, nimesulide is contraindicated in pregnancy and lactation. The use of Nimesil can negatively affect female fertility and is not recommended for women planning a pregnancy. When planning pregnancy, consultation with the doctor is necessary.

Simultaneous intake of Nimesil with alcohol is prohibited because of the risk of developing bleeding from the gastrointestinal tract.

There are data on the occurrence in rare casesskin reactions (such as exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) on nimesulide as well as other NSAIDs. At the first signs of skin rashes, lesions of mucous membranes or other signs of an allergic reaction, the drug Nimesil should be stopped.

Effect of the drug on the ability to drive vehicles and manage mechanisms

Effect of Nimesil on the ability tothe driving of vehicles and the management of mechanisms have not been studied, therefore, during the period of treatment with Nimesil, caution should be exercised when driving vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

When combined with glucocorticosteroids, the risk of a gastrointestinal ulcer or bleeding increases.

When combined with antiplateletagents and selective serotonin reuptake inhibitors (SSRIs), for example, fluoxetine increases the risk of gastrointestinal bleeding.

NSAIDs can enhance the effect of anticoagulants,such as warfarin. Because of the increased risk of bleeding, this combination is not recommended and is contraindicated in patients with severe coagulation disorders. If combined therapy can still be avoided, careful monitoring of blood coagulation should be carried out.

NSAIDs may reduce the effect of diuretics.

In healthy volunteers, nimesulide temporarily reduces the excretion of sodium by furosemide, to a lesser extent - the excretion of potassium, and reduces the actual diuretic effect.

The combined administration of Nimesil and furosemide results inreduction (approximately 20%) of the area under the concentration-time curve (AUC) and a decrease in cumulative furosemide excretion without altering the renal clearance of furosemide.

Co-administration of furosemide and nimesulide requires caution in patients with impaired renal and cardiac function.

ACE inhibitors and angiotensin 2 receptor antagonists

NSAIDs can reduce the effect of antihypertensivepreparations. In patients with mild to moderate renal failure (CK 30-80 ml / min), concomitant administration of ACE inhibitors, angiotensin-2 receptor antagonists, or agents that inhibit the system of cycloxygenase (NSAIDs, antiplatelet agents) may further impair kidney function and cause acute renal failure , which, as a rule, is reversible. These interactions should be considered in patients taking Nimesil in combination with ACE inhibitors or angiotensin II receptor antagonists. Therefore, joint administration of these drugs should be administered with caution, especially for elderly patients. Patients should receive a sufficient amount of fluid, and renal function should be carefully monitored after the initiation of co-therapy.

Pharmacokinetic interactions with other drugs

There is evidence that NSAIDs reduce clearancelithium, which leads to an increase in the concentration of lithium in blood plasma and its toxicity. When nimesulide is prescribed, patients receiving lithium therapy should be monitored regularly for plasma lithium concentrations.

Clinically significant interactions with glibenclamide, theophylline, digoxin, cimetidine and antacid preparations (for example, a combination of aluminum and magnesium hydroxides) were not observed.

When nimesulide is administered less than 24 hours beforeor after taking methotrexate, care needs to be taken, as in such cases the level of methotrexate in the plasma and, accordingly, the toxic effects of this drug may increase.

In connection with the effect on renal prostaglandins, inhibitors of prostaglandin synthetases, to which nimesulide belongs, may increase the nephrotoxicity of cyclosporins.

Interaction of other drugs with nimesulide

Studies have shown that nimesulide is being replacedfrom binding sites to tolbutamide, salicylic acid and valproic acid. Despite the fact that these interactions were determined in blood plasma, these effects were not observed during the clinical application of the drug.

Analogues of the medicinal product Nimesil

Structural analogs for the active substance:

In the absence of analogues of the drug according to the currentsubstance, you can click on the links below for the diseases, from which the appropriate drug helps and see the available analogs for therapeutic effects.


Edited news: admin - 16-01-2015, 14:27
Cause: update of the data on the preparation